Analyzing Esperion Therapeutics Inc. (ESPR)’s Gross, Operating, Pretax, and Net Margins

As of right now, Esperion Therapeutics Inc. [ESPR] is trading at $2.58, saw in change for the day. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ESPR shares have gain 17.81% over the last week, with a monthly amount drifted -6.18%, and not seem to be holding up well over a long-time horizon.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

On 1, February 2024, RFK, Esperion Therapeutics Announce 2024 Promotional Schedule. In a post published today on Yahoo Finance, NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024.

From an analyst’s perspective:

Esperion Therapeutics Inc. [NASDAQ: ESPR] stock has seen the most recent analyst activity on January 03, 2024, when BofA Securities downgraded its rating to a Neutral.

Through the last year, Esperion Therapeutics Inc.’s stock price ranged from $0.70 to $6.74. Esperion Therapeutics Inc. [NASDAQ: ESPR] shares were valued at $2.58 at the most recent close of the market.

Analyzing the ESPR fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.51 points at the first support level, and at 2.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.70, and for the 2nd resistance point, it is at 2.82.

Esperion Therapeutics Inc. [ESPR] reported earnings per share of -$0.37 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.43/share, meaning a difference of $0.06 and a surprise factor of 14.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.46 per share as compared to estimates of -$0.61 per share, a difference of $0.15 representing a surprise of 24.60%.

Ratios To Look Out For

It is important to note that Esperion Therapeutics Inc. [NASDAQ:ESPR] has a current ratio of 1.58.

Transactions by insiders

Recent insider trading involved Warren Eric, Chief Commercial Officer, that happened on Sep 20 when 742.0 shares were sold. Chief Commercial Officer, Warren Eric completed a deal on Aug 18 to sell 243.0 shares. Meanwhile, Chief Commercial Officer Warren Eric sold 106.0 shares on Jul 19.

Related Posts